Intervention not reported
PFS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention probably leads to lower PFS (at 3 years) (moderate certainty).
1 finding from 1 review
- Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes onlyHR 0.64 [0.55, 0.74]3 studies · 1421 participantsModerate